Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
Stopped early · Phase 3
Conditions studied: Skin Aging
In brief
This study will evaluate the long-term safety of botulinum toxin type A for the treatment of moderate to severe crow's feet lines after repeat application.
Key facts
- Study ID
- NCT01818076
- Run by
- Revance Therapeutics, Inc.
- People needed
- 311
- Starts
- 2013-02-01
- Expected to finish
- 2013-12-01
- Last updated by the study team
- 2014-05-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Moderate to severe crow's feet lines
- Female or male, 18 years of age and above and in good general health
- Women of childbearing potential must agree to use an effective method of birth control during the course of the study
You may not qualify if…
- Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A
- Muscle weakness or paralysis, particularly in the area receiving study treatment
- Active skin disease or irritation at the treatment area
- Deep dermal scarring, or inability to smooth out the crow's feet lines to be treated by manually spreading the skin apart
- Treatment with botulinum toxin type A for crow's feet lines in the last 3 months
- Chemical peel during the 9 months prior to treatment
- Use of prescription retinoid products during the 3 months prior to treatment
Where it is running
- Nashville Centre for Laser and Facial Surgery — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.